KLOX Technologies announces the sale of its in-office whitening kit and teeth-whitening pen businesses to Valeant

KLOX Technologies announces the sale of its in-office whitening kit and 
teeth-whitening pen businesses to Valeant Pharmaceuticals International, Inc. 
KLOX Technologies to focus its innovative biophotonic technology and resources 
on medically focused solutions in dermatology, tissue repair and dentistry 
LAVAL, QC, Nov. 29, 2012 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" or the 
"Company") is pleased to announce that it has entered into an agreement for 
the sale (the "Sale") of its professional in-dentists-office whitening kit 
business as well as its teeth-whitening pen business ("Business") to Valeant 
Pharmaceuticals International, Inc. (NYSE/TSX: VRX), which will be managed by 
its dental affiliate OraPharma, Inc. ("Valeant"). As part of the Sale, KLOX 
is assigning to Valeant its rights in the Business. Valeant is planning to 
launch the products in the U.S. in early 2013 and is planning a smooth 
transition with existing partners. Financial terms include an upfront payment 
and a double-digit royalty stream based on product sales during the next 10 
years. 
"We are pleased to have concluded the transaction with Valeant, a highly 
regarded company. Valeant has conveyed its commitment towards taking our 
product lines to their full potential through their well-established 
commercial capabilities in the United States and around the world", said Dr. 
Lise Hébert, President & CEO of KLOX. "This is a very exciting opportunity 
for all of us and at KLOX we will continue building our value-creation 
strategy and invest in our innovation and development for the advancement of 
medical solutions in the fields of dermatology, dentistry and tissue repair. 
Our European registration trial to treat moderate-to-severe acne is scheduled 
to complete in a few weeks and the evaluation of the safety and efficacy of 
our devices to treat unresponsive chronic wounds in America and Europe is 
underway. The next 24 months will be important for KLOX in the delivery to the 
market of brand new solutions to address what still today remain unmet medical 
needs in the treatment of acne and the advanced wound care fields", she 
concluded. 
"This acquisition is a very good strategic fit for Valeant and for OraPharma, 
as Valeant continues to enhance its commercial capabilities within the dental 
market segment," said Mr. Steven Sembler, Senior Vice-President at OraPharma. 
"KLOX has successfully developed and brought forward innovative technology and 
clinically meaningful products that represent a significant commercial 
opportunity in the whitening field in many geographies around the world. We 
immediately want to build upon those capabilities and use both our commercial 
organization and network of partners to leverage them into attractive product 
propositions and to create additional value for both patients and clinicians," 
he concluded. 
About KLOX Technologies: Leveraging light-based biophotonic technologies
KLOX is a privately-owned company focused on the development and 
commercialization of a unique, non-invasive biophotonic technology using a 
primary device consisting of a multiple LED lighting system that interacts 
with an oxygen-rich gel containing light-trapping molecules. KLOX's cosmetics 
and medical devices are destined for the rapidly growing aesthetics, dental, 
dermatological and medical markets. Its dentistry portfolio included 
innovative teeth whitening treatments like FAST&MILD™ and LifeSmile™. 
Treatments for periodontitis are also currently under development for medical 
applications. 
About the Business
FAST&MILD™: Effective, non-invasive and affordable
FAST&MILD™ is positioned to rapidly take a strong foothold in the teeth 
whitening market. It is an advanced chair-side whitening system that uses 
biophotonic technology to whiten teeth naturally. This unique TRUE light 
activated system delivers result in as a little as 30 minutes, with virtually 
no sensitivity. The reduced treatment time translates into a gentler procedure 
providing you with a brilliant, healthy looking smile. 
FAST&MILD™ is highly competitive compared to other teeth whitening products 
in the market today. From the dentist's perspective, it is capital efficient, 
with no capital investment required. The procedure can be completed in about 
half the time required for competitive products, allowing for increased 
efficiency in dentist's office. 
LifeSmile™: a whitening pen with unique features
LifeSmile™ by KLOX Technologies advanced teeth brightening pen is a 
revolutionary teeth whitening pen designed by dentists to quickly and 
effectively clean away surface stains from your teeth, at affordable prices. 
Conceived for life on the go, whitening your teeth has never been easier! 
LifeSmile™ is no bigger than a pen, its sleek compact design means it can go 
anywhere you do. 
Medical segments
In the dermatology segment, KLOX's skin rejuvenation product SKR-1 is in 
regulatory compliance in Canada, United States and Europe and is now ready to 
be fully commercialized. In addition, KLOX has also developed a promising Acne 
treatment system (AC-1), which is currently in a final registration trial 
towards approval in Europe. The trial is near completion with an encouraging 
safety profile and the data is planned for the first quarter of 2013. 
Finally, KLOX is developing (WH-1), an innovative light-based treatment for 
the multi-billion dollar advanced wound care market. Its proprietary 
technology, which has been fundamentally designed to operate as a light 
enhancing technology, combines multi-LED light phototherapy effect, an 
externally applied oxidant and certain chromophores designed to enhance 
breakdown of oxidant as well as skin's light absorption. The system is being 
investigated to treat pressure sores, diabetic and venous leg ulcers with the 
goal to significantly accelerate healing in a favorable environment. 
For further information on KLOX, please visit the Company's website: 
www.kloxtechnologies.com 
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational 
specialty pharmaceutical company that develops, manufactures and markets a 
broad range of pharmaceutical products primarily in the areas of dermatology, 
neurology and branded generics. More information about Valeant 
Pharmaceuticals International, Inc. can be found at www.valeant.com 
Forward Looking Statements 
Certain statements contained in this presentation, other than statements of 
fact that are independently verifiable at the date hereof, may constitute 
forward-looking statements. Examples of such forward-looking statements 
include those regarding cosmetics and medical devices and medical applications 
and clinical trials and the status and related results thereto, as well those 
regarding continuing and further development efforts. Such statements, based 
as they are on the current analysis and expectations of management, inherently 
involve numerous risks and uncertainties, known and unknown, many of which are 
beyond KLOX Technologies Inc.'s control. Such risks include but are not 
limited to: the impact of general economic conditions, general conditions in 
the medical, cosmetics and/or consumer goods industries, changes in the 
regulatory environment in the jurisdictions in which KLOX Technologies Inc. 
does business, financial and commercial markets volatility, fluctuations in 
costs, and changes to the competitive environment, as well as other risks. 
Consequently, actual future results may differ materially from the anticipated 
results expressed in the forward-looking statements. In the case of 
forward-looking statements regarding investigational product candidates and 
continuing and further development efforts, specific risks which could cause 
actual results to differ materially from KLOX Technologies Inc.'s current 
analysis and expectations include: failure to demonstrate the safety, 
tolerability and efficacy of our products, final and quality controlled 
verification of data and the related analyses, and the expense and uncertainty 
of obtaining regulatory approval. 
Business, Consumer and Marketing Media: Roch Landriault NATIONAL Public 
Relations +1 (514) 843-2345 
SOURCE: Klox Technologies Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/November2012/29/c4604.html 
CO: Klox Technologies Inc.
ST: Quebec
NI: MTC MNA  
-0- Nov/29/2012 11:00 GMT